Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

This is a phase 1 safety and tolerability study of a new drug called GIM-531 in people with advanced solid tumors that have progressed after standard therapies. The main goal is to determine the safest dose and assess any side effects. **You may be eligible if...** - You have a locally advanced or metastatic solid tumor that has progressed despite standard treatment, or no standard treatment exists - You are in good overall health (ECOG 0–1) - Your heart, kidney, and liver function meet study requirements - You are able to provide a tumor biopsy or have recent archived tumor tissue - You are willing to use contraception during and after treatment **You may NOT be eligible if...** - You have participated in another experimental drug study within 4 weeks (or 5 drug half-lives) - You are pregnant - Your organ function is significantly impaired - You are unable to comply with study visits and procedures Talk to your doctor to see if this trial is right for you.